Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals Inc. (GB:0A4W)
:0A4W
RESEARCH TOOLSreports
0A4W Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.18 - $20.48
Previous CloseN/A
Volume1.31K
Average Volume (3M)439.00
Market Cap
$2.87B
Enterprise Value$2.04B
Total Cash (Recent Filing)$319.59M
Total Debt (Recent Filing)$51.99M
Price to Earnings (P/E)13.7
Beta0.27
Next Earnings
May 13, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.36
Shares Outstanding166,788,510
10 Day Avg. Volume216
30 Day Avg. Volume439
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.06
Price to Cash Flow (P/CF)18.10
P/FCF Ratio18.10
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda20.90
Forecast
1Y Price Target
$26.14Price Target Upside40.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Drug Acceptance And Patient OutcomesSurvey data shows decreased diarrhea severity, decreased discontinuations, and improved quality of life for Rett patients on Daybue.
Financial PerformanceAcadia continues to push pedals on the Daybue sales with the fourth quarter revenue of $97M beating the consensus of $94M.
Bears Say
Sales ExpectationsDaybue's net sales guidance for 2025 falls short of market expectations, which could indicate potential challenges for the brand.
---
Options Prices
Currently, No data available
---
Ownership Overview
24.05% Insiders
15.15% Mutual Funds
0.34% Other Institutional Investors
37.25% Public Companies and Individual Investors
0A4W FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest share price was $14.18 and its highest was $20.48 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $2.87B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is May 13, 2025 which is in 62 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on Feb 26, 2025. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.216 by $0.644.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is -0.02.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 166,788,510 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.86 in its last earnings report, beating expectations of $0.216. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in GB:0A4W
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.14 (40.39% Upside)
$26.14 (40.39% Upside)
Blogger Sentiment
Bullish
GB:0A4W Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
38.89%
Trailing 12-Months
Asset Growth
58.59%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
0A4W Company Deck
---
0A4W Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial results, pipeline expansion, and global growth plans, but also acknowledged challenges in revenue guidance due to pricing and regulatory uncertainties. Despite these hurdles, the company remains optimistic about its future growth and strategic initiatives.Read More>---
0A4W Stock 12 Month Forecast
Average Price Target
$26.14
▲(40.39% Upside)
Technical Analysis
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering 0A4W
1 Year
1 Year Success Rate
18/34 ratings generated profit
1 Year Average Return
+21.38%
reiterated a buy rating 14 days ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 55.88% of your transactions generating a profit, with an average return of +21.38% per trade.
---